Integrated bioinformatics analysis and experimental validation reveal Pevonedistat as a promising therapeutic agent modulating the CRL4-DTL-p21/p53 axis in nasopharyngeal carcinoma. This evidence concerns the gene DTL and nasopharyngeal carcinoma.